A single‐centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost
Haemophilia · 2024
DOI: 10.1111/hae.14909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Louise Favrelle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de pharmacie, Pierre-Bénite, France. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Ankle, Hemophilia A, Joint Diseases, Arthritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
In patients with haemophilia, repeated bleeding in large joints leads to chronic haemophilic arthropathy, a rare disease that can be managed surgically with ankle arthrodesis or with total ankle replacement (TAR). TAR has been reported to provide good surgical results in the medium/long‐term and allow preservation of joint mobility but the medical therapeutic management of the patients has not been described.
Aim
To describe the medical therapeutic management of TAR.
Methods
All patients with haemophilia A/B, with haemophilic ankle arthropathy, and who underwent TAR between April 2006 and October 2019 were retrospectively included. Factor consumption, perioperative and early complications, volume of blood lost, and orthopaedic data were collected.
Results
A total of 25 patients underwent 29 TAR (mean age was 44.7 years [range: 26–65]). In the 17 patients with HA without history of anti‐FVIII inhibitor, the mean ± SD consumption the day of surgery was 116 ± 16 UI/kg when clotting factors were administered by continuous infusion, 106 ± 13 UI/kg when SHL factors were administered by bolus infusion, and 75 ± 22 UI/kg when EHL factors were administered by bolus infusion. During hospitalisation, the mean factor cost was €38,073 (83.7% of the total cost of surgery). Mean blood loss was significantly lower in patients treated with tranexamic acid (164 mL, range: 40–300) than in those not (300 mL, range: 70–800; p = .01). Six patients had haematoma. The 10‐year survival free of any prosthesis removal/arthrodesis was estimated to be 92.2% (95% CI [83; 100]).
Conclusion
The medical therapeutic management of TAR is complex, carried out by a multidisciplinary team but effective in avoiding the occurrence of complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de pharmacie, Pierre-Bénite, France.
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Chirurgie Orthopédique et Traumatologique, Pierre-Bénite, France.
- Université Lyon 1, IFSTTAR, LBMC UMR-T 9406 - Laboratoire de Biomécanique et Mécanique des Chocs, Bron, France.
- Hospices Civils de Lyon, Groupement Hospitalier Est, Service d'Hémostase clinique, Bron, France.
- Hospices Civils de Lyon, Groupement Hospitalier Est, Service de pharmacie, Bron, France.
ORCID-Profile: Louise Favrelle
Zitieren
APA
Favrelle, L., Masson, J. B., Parat, S., Carre, E., Fessy, M., Rioufol, C., Lienhart, A., Chamouard, V., & Besse, J. L. (2024). A single‐centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost. Haemophilia. https://doi.org/10.1111/hae.14909
Vancouver
Favrelle L, Masson JB, Parat S, Carre E, Fessy M, Rioufol C, et al. A single‐centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost. Haemophilia. 2024. doi:10.1111/hae.14909
BibTeX
@article{Favrelle2024,
author = {Favrelle, Louise and Masson, Jean-Baptiste and Parat, Stéphanie and Carre, Emmanuelle and Fessy, Michel and Rioufol, Catherine and Lienhart, Anne and Chamouard, Valérie and Besse, Jean-Luc},
title = {A single‐centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.14909}
}
EUVIMED